checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


Low incidence of laboratory abnormalities1,2

There is no label-required laboratory prescreening or ongoing monitoring during treatment3

 

MARKED ABNORMALITIES IN LABORATORY PARAMETERS1,2

otezla selected marked abnormalities in laboratory parameters
a

Pooled data from ESTEEM® 1 and ESTEEM 2. Includes all patients who received OTEZLA regardless of when OTEZLA exposure started. OTEZLA exposure is based on each patient’s total exposure to OTEZLA, defined as the time interval between the date of the first dose and the date of the last dose, inclusive.

b

Did not have to be drawn when patient was fasting.

  • No clinically meaningful effects on laboratory parameters were reported during short- or long-term treatment1,2

ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; ULN, upper limit of normal.

References: 1. Data on file, Celgene Corporation. 2. Papp K, Sobell JM, Shah K, et al. Safety and Tolerability of Apremilast Up to 182 Weeks: Pooled Analyses From Phase 3 Clinical Trials. Presented at: the 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC. 3. OTEZLA Summary of Product Characteristics. Stockley Park, Uxbridge, UK: Celgene Europe, Ltd; 2016.


Select an e-mail client to share

close x